目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T6479 | VEGFR FGFR FLT PDGFR c-Kit | ||
Dovitinib lactate hydrate (TKI258) 是一种多靶点的酪氨酸激酶抑制剂,抑制 FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和 PDGFRα/β的 IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T7104 | VEGFR FGFR FLT PDGFR c-Kit | ||
Dovitinib lactate (TKI-258 lactate) 是一种多靶点的酪氨酸激酶抑制剂,抑制FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和PDGFRα/β的IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T40923 | Others | ||
Calcium lactate (Conclyte calcium) 被饮料工业用作强化果汁的钙源。Calcium lactate 促进豆芽生长和植酸降解。 | |||
T5967 | Others Antibacterial | ||
Ethacridine lactate (Acrinol) 是一种聚 (ADP-核糖) 糖水解酶 (PARG) 抑制剂,也是一种抗菌剂和流产剂。它有抗金黄色葡萄球菌和其他革兰氏阳性球菌的活性。 | |||
T4103 | Others | ||
(L)-Sodium lactate (Sodium L-Lactate) 是由乳酸脱氢酶从丙酮酸中产生的。它在无氧糖酵解过程中或增殖活跃的细胞中产生。 它在人和动物的血液和肌肉液中少量存在。剧烈运动后,肌肉和血液中的乳酸浓度会增加。 它也存在于肝脏、肾脏、胸腺、人羊水以及其他器官和体液中。 | |||
T8785 | DNA/RNA Synthesis TGF-beta/Smad | ||
HALOFUGINONE LACTATE 是 febrifugine 的卤化衍生物,它是一种天然的含有喹唑啉酮的化合物,存在于中草药 D. febrifuga 中。Halofuginone 以 ATP 依赖性方式抑制脯氨酰-tRNA 合成酶,Ki 为 18.3 nM。 Halofuginone 是 I 型胶原合成的特异性抑制剂,通过抑制 TGF-β 活性来减轻骨关节炎 (OA) | |||
T1440 | Antibacterial Antibiotic | ||
Ethacridine lactate monohydrate 是一种聚 (ADP-核糖) 糖基水解酶 (PARG) 抑制剂,有抗金黄色葡萄球菌和其他革兰氏阳性球菌的活性。它也是抗菌剂和流产剂。 | |||
T32809 | |||
L-Lactate ion is the conjugate base of lactic acid. | |||
T26300 | |||
Tylosin, lactate is a bacteriostat feed additive used in veterinary medicine. It is a macrolide antibiotic that has a broad spectrum of activity against Gram-positive organisms but a limited range of Gram-negative organisms. It is found naturally as a fer | |||
T12117 | Others | ||
MSI-1436 lactate is a selective, non-competitive the enzyme protein-tyrosine phosphatase 1B (PTB1B)inhibitor(IC50 of appr 1 μM) |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04180 | PfLDH Protein, P. falciparum, Recombinant (His) | P. falciparum | E. coli | ||
Plasmodium falciparum lactate dehydrogenase (PfLDH) is a key enzyme for energy generation of malarial parasites and is considered to be a potential antimalarial target. The ability of PfLDH- or PfIDEh-based immuno-PCR assays to detect <1 parasite/microL suggests that improvements of bound antibody sensor technology may greatly increase the sensitivity of malaria rapid diagnostic tests. The PfLDH test could be used to detect failures and, therefore, to assess anti-malarial efficacy.
|
|||||
TMPY-04241 | LDHA Protein, Rat, Recombinant (His) | Rat | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPY-00010 | LDHA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPJ-00797 | LDHB Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase B Chain (LDH-B) is a member of the lactate dehydrogenase family that consists of three members, LDH-A, LDH-B and LDH-C; members of this family function as powerful markers for germ cell tumors. LDH-B is an oxidoreductase that catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. It converts pyruvate to lactate when oxygen is absent or in short supply and it performs the reverse reaction during the Cori cycle in the liver. It is also called Hydroxybutyrate Dehydrogenase (HBD) due to its ability to catalyze the oxidation of hydroxybutyrate.
|
|||||
TMPH-03136 | L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) | Plasmodium berghei | E. coli | ||
L-lactate dehydrogenase Protein, Plasmodium berghei, Recombinant (His & Myc) is expressed in E. coli.
|
|||||
TMPJ-00724 | LDHA Protein, Human, Recombinant (His) | Human | E. coli | ||
L-Lactate Dehydrogenase A Chain (LDHA) is an enzyme that catalyzes the conversion of L-lactate and NAD+ to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA contains an N-terminal coenzyme binding region, a central catalytic site, and at least nine utilized Lys acetylation and two Tyr phosphorylation sites. LDHA belongs to the lactate dehydrogenase family, expressed predominantly in muscle tissue. LDHA mutations have been linked to exertional myoglobinuria.
|
|||||
TMPH-00693 | L-lactate dehydrogenase Protein, E. coli O9:H4, Recombinant (His) | E. coli | E. coli | ||
Catalyzes the conversion of L-lactate to pyruvate. Is coupled to the respiratory chain.
|
|||||
TMPY-04826 | LILRB5/CD85c Protein, Human, Recombinant (His) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01696 | SLC16A4 Protein, Human, Recombinant (His) | Human | E. coli | ||
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate.
|
|||||
TMPY-05186 | LILRB5/CD85c Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPY-06273 | LILRB5/CD85c Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms.
|
|||||
TMPH-01202 | D2HGDH Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the oxidation of D-2-hydroxyglutarate (D-2-HG) to alpha-ketoglutarate. Also catalyzes the oxidation of other D-2-hydroxyacids, such as D-malate (D-MAL) and D-lactate (D-LAC). Exhibits high activities towards D-2-HG and D-MAL but a very weak activity towards D-LAC.
|
|||||
TMPY-02288 | Glyoxalase II/HAGH Protein, Human, Recombinant (His) | Human | E. coli | ||
HAGH (Hydroxyacylglutathione Hydrolase) is a Protein Coding gene. 3 alternative splicing and alternative initiation of human isoforms have been reported. The enzyme encoded by this gene is classified as a thioesterase and is responsible for the hydrolysis of S-lactoyl-glutathione to reduced glutathione and D-lactate. HAGH belongs to the Metallo-beta-lactamase superfamily. HAGH is widely expressed in the kidney, liver, and other tissues. Diseases associated with HAGH include Hydroxyacyl Glutathione Hydrolase Deficiency. Among its related pathways are Pyruvate metabolism and Citric Acid (TCA) cycle and Metabolism. The human and rodent forms of glyoxalase II (HAGH) can readily be separated by starch gel electrophoretic procedures.
|
|||||
TMPH-01860 | PCK1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Cytosolic phosphoenolpyruvate carboxykinase that catalyzes the reversible decarboxylation and phosphorylation of oxaloacetate (OAA) and acts as the rate-limiting enzyme in gluconeogenesis. Regulates cataplerosis and anaplerosis, the processes that control the levels of metabolic intermediates in the citric acid cycle. At low glucose levels, it catalyzes the cataplerotic conversion of oxaloacetate to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. At high glucose levels, it catalyzes the anaplerotic conversion of phosphoenolpyruvate to oxaloacetate. Acts as a regulator of formation and maintenance of memory CD8(+) T-cells: up-regulated in these cells, where it generates phosphoenolpyruvate, via gluconeogenesis. The resultant phosphoenolpyruvate flows to glycogen and pentose phosphate pathway, which is essential for memory CD8(+) T-cells homeostasis. In addition to the phosphoenolpyruvate carboxykinase activity, also acts as a protein kinase when phosphorylated at Ser-90: phosphorylation at Ser-90 by AKT1 reduces the binding affinity to oxaloacetate and promotes an atypical serine protein kinase activity using GTP as donor. The protein kinase activity regulates lipogenesis: upon phosphorylation at Ser-90, translocates to the endoplasmic reticulum and catalyzes phosphorylation of INSIG proteins (INSIG1 and INSIG2), thereby disrupting the interaction between INSIG proteins and SCAP and promoting nuclear translocation of SREBP proteins (SREBF1/SREBP1 or SREBF2/SREBP2) and subsequent transcription of downstream lipogenesis-related genes.
|